Investigating how FOSL1 affects cancer stem cells in head and neck cancer treatment
FOSL1-super-enhancers define cisplatin-enriched cancer stem cells in HNSCC
This study is looking at how a protein called FOSL1 affects head and neck cancer cells and their ability to resist the chemotherapy drug cisplatin, with the goal of finding better treatments for patients who struggle with this resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11181285 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of FOSL1 in head and neck squamous cell carcinoma (HNSCC) and its relationship with the chemotherapeutic drug cisplatin. The study aims to identify how FOSL1 super-enhancers contribute to the survival and resistance of cancer stem cells (CSCs) to cisplatin treatment. By exploring the mechanisms behind FOSL1's influence on CSCs, the researchers hope to develop targeted therapies that can overcome cisplatin resistance, potentially improving treatment outcomes for patients. The approach includes using advanced techniques to analyze the genetic and functional properties of these cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma who are undergoing cisplatin treatment.
Not a fit: Patients with head and neck cancer who are not receiving cisplatin or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target and eliminate resistant cancer stem cells in head and neck cancer patients.
How similar studies have performed: Previous research has shown promise in targeting cancer stem cells to overcome drug resistance, suggesting that this approach may yield significant advancements.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Li, Jiong — Virginia Commonwealth University
- Study coordinator: Li, Jiong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.